Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma
Abstract Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-92115-0 |
id |
doaj-e3d3131177f044b8a16fa6a095441956 |
---|---|
record_format |
Article |
spelling |
doaj-e3d3131177f044b8a16fa6a0954419562021-06-20T11:37:30ZengNature Publishing GroupScientific Reports2045-23222021-06-0111111010.1038/s41598-021-92115-0Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinomaQi-Fan Yang0Di Wu1Jian Wang2Li Ba3Chen Tian4Yu-Ting Liu5Yue Hu6Li Liu7Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five public datasets, consisting of 687 cases, we developed an immune-related prognostic model (IPM) according to immune genes from ImmPort database. Then, we comprehensively analyzed the immune microenvironment and mutation burden that are significantly associated with this model. According to the IPM, patients were stratified into high- and low-risk groups with markedly distinct survival benefits. We found that patients with high immune risk possessed a higher proportion of immunosuppressive cells such as macrophages M0, and presented higher expression of CD47, CD73, SIRPA, and TIM-3. Moreover, When further stratified based on the tumor mutation burden (TMB) and risk score, patients with high TMB and low immune risk had a remarkable prolonged overall survival compared to patients with low TMB and high immune risk. Finally, a nomogram combing the IPM with clinical factors was established to provide a more precise evaluation of prognosis. The proposed immune relevant model is a promising biomarker for predicting overall survival in stage I–III LUSC. Thus, it may shed light on identifying patient subset at high risk of adverse prognosis from an immunological perspective.https://doi.org/10.1038/s41598-021-92115-0 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qi-Fan Yang Di Wu Jian Wang Li Ba Chen Tian Yu-Ting Liu Yue Hu Li Liu |
spellingShingle |
Qi-Fan Yang Di Wu Jian Wang Li Ba Chen Tian Yu-Ting Liu Yue Hu Li Liu Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma Scientific Reports |
author_facet |
Qi-Fan Yang Di Wu Jian Wang Li Ba Chen Tian Yu-Ting Liu Yue Hu Li Liu |
author_sort |
Qi-Fan Yang |
title |
Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma |
title_short |
Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma |
title_full |
Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma |
title_fullStr |
Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma |
title_full_unstemmed |
Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma |
title_sort |
development and validation of an individualized immune prognostic model in stage i–iii lung squamous cell carcinoma |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-06-01 |
description |
Abstract Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five public datasets, consisting of 687 cases, we developed an immune-related prognostic model (IPM) according to immune genes from ImmPort database. Then, we comprehensively analyzed the immune microenvironment and mutation burden that are significantly associated with this model. According to the IPM, patients were stratified into high- and low-risk groups with markedly distinct survival benefits. We found that patients with high immune risk possessed a higher proportion of immunosuppressive cells such as macrophages M0, and presented higher expression of CD47, CD73, SIRPA, and TIM-3. Moreover, When further stratified based on the tumor mutation burden (TMB) and risk score, patients with high TMB and low immune risk had a remarkable prolonged overall survival compared to patients with low TMB and high immune risk. Finally, a nomogram combing the IPM with clinical factors was established to provide a more precise evaluation of prognosis. The proposed immune relevant model is a promising biomarker for predicting overall survival in stage I–III LUSC. Thus, it may shed light on identifying patient subset at high risk of adverse prognosis from an immunological perspective. |
url |
https://doi.org/10.1038/s41598-021-92115-0 |
work_keys_str_mv |
AT qifanyang developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT diwu developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT jianwang developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT liba developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT chentian developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT yutingliu developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT yuehu developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma AT liliu developmentandvalidationofanindividualizedimmuneprognosticmodelinstageiiiilungsquamouscellcarcinoma |
_version_ |
1721369925383094272 |